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Background: Anemia is a strong predictor of mortality and poor quality of life among persons with either renal
impairment or HIV infection. In this study, we investigated the prevalence of anemia and its association with renal
insufficiency among HIV infected patients initiating ART at a hospital in Northeast Ethiopia.
Methods: In this retrospective cohort study, records of 373 patients on ART were selected in Dessie Referral hospital,
South Wollo, Northeast Ethiopia from September 2010 to August 2013. Socio-demographic and clinical characteristics
of the study patients were collected using standardized data extraction instrument. The abbreviated 4-variable
Modification of Diet in Renal Disease (MDRD) study equation was used to estimate renal function (GFR) from
serum creatinine. SPSS version 20.0 statistical software was used for data analysis.
Results: The prevalence of anemia at the time of ART initiation was 34.4%; with 20.5, 12.3 and 1.6% mild, moderate
and severe anemia, respectively. Renal insufficiency was present in 27.9% of patients and was associated with a high
prevalence of anemia (74%). The prevalence of anemia increased with stage of insufficiency, from 23.7% in stage 1 to
100% in stage 4. Impaired renal function (eGFR < 60 mL/min/1.73 m2) was associated with a higher risk of all
forms of anemia; i.e., mild (AOR = 3.96; 95% CI: 2.76–5.69), moderate (AOR = 2.21; 95% CI: 1.16–4.19) and severe
anemia (AOR = 5.89; 95% CI: 1.02–12.03).
Conclusion: HIV infected patients with renal insufficiency had a higher prevalence of anemia compared to
patients with normal renal function. Thus, screening of these patients for anemia and renal insufficiency at base
line should be critical not only to reduce mortality but also to improve clinical outcomes.
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Anemia is recognized to be the most common
hematological abnormalities in patients with human
immunodeficiency virus (HIV) infection and is an im-
portant clinical problem in these patients both before
and after the advent of combination antiretroviral therapy
(ART) [1, 2]. Evidences indicate that anemia among these
patients was associated with a much faster rate of disease
progression and decreased quality of life, and was a strong
prognostic marker for death [3–5]. Depending on the
study setting, anemia can be found in 63–95% of those
with HIV infection at some point during the course of* Correspondence: temafiseha@gmail.com
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etiologic factors leading to decreased red blood cell (RBC)
production, increased RBC destruction, or ineffective RBC
production [6, 7]. Patients with more advanced HIV
disease or a lower CD4 cell count had higher rates of
anemia [8].
As in HIV, anemia occurs commonly in renal insuffi-
ciency, the result of decreased production of erythro-
poietin, a signaling molecule that stimulates red blood
cell production. A decline in renal function appeared to
constitute a significant risk of anemia, and the preva-
lence of anemia increases significantly with progressive
renal impairment [9]. Among persons with renal insuf-
ficiency, anemia has been associated with substantial
clinical and public health outcomes including increasedle is distributed under the terms of the Creative Commons Attribution 4.0
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As lower hemoglobin levels associate with major clinical
outcomes at all levels of function, treatment of anemia
ameliorates the loss of kidney function and progression to
renal failure and improves quality of life and various
health measures.
Anemia is a strong predictor of mortality and poor
quality of life among persons with either renal impair-
ment or HIV infection [3, 5, 10], and a study on the risk
of anemia suggest that HIV infection and impaired renal
function act synergistically to increase the risk for the
development of anemia. According to this study, HIV
infected persons with impaired renal function had 5–15
times greater risk of developing anemia than those with
either risk factor alone, suggesting a higher risk of
anemia associated morbidity and mortality [11]. Despite
the fact that HIV infected persons with impaired renal
function have a higher risk of developing anemia, and
thus, suffer extra morbidity and mortality than those
without renal impairment; relatively little is known
about its prevalence among HIV infected adults in
Ethiopia. In this study, we assessed the prevalence of
anemia and its association with renal insufficiency
among HIV infected adults at the time of ART initiation
in Dessie referral hospital of Southern Wollo, Northeast
Ethiopia.
Methods
Study setting and study population
A retrospective study was conducted by reviewing hos-
pital data of patients who were receiving HAART at the
HIV clinic of Dessie Referral Hospital (DRH) in Southern
Wollo, Northeast Ethiopia from September 2010 to
August 2013. The hospital serves as a referral center
for the surrounding zones and provides HIV/AIDS
interventions including free diagnosis, treatment and
monitoring. The Hospital launched Antiretroviral
Therapy (ART) in September 2003, and 5,245 were on
ART and 502 were on pre-ART during data collection.
Among those, a total of 373 (140 males and 233
females) HIV infected individuals data at the time of
ART initiation were randomly selected for this study.
The age range of the patients was above 18 years.
Patients who had incomplete recording at baseline and
those who were pregnant at the time of ART initiation
were excluded from this study. Patients with baseline
evidence of hospitalization, acute illnesses (fever) and
dialysis therapy were also excluded.
Before collection of the data, a data extraction tool
was prepared and pre tested. Additionally, the nurses
who were selected to collect the data were given one day
training on the data extraction tool and how to collect
data from registers to ensure no selection or information
bias was introduced at the time of data collection.During data collection, the principal investigator super-
vises the data collectors and examined the tools for
accuracy and completeness.
Laboratory measurements and definitions
Hemoglobin (Hgb) values were determined using the
hematology analyzer Cell-Dyn 1800 (Abbott Laboratories
Diagnostics Division, USA) and CD4+ T cells were assayed
using the BD FACSCOUNT system (Becton Dickenson
and Company, California, USA). Anemia was defined
according to the WHO criteria: Hgb concentration
<13 g/dl for males and < 12 g/dl for females. We classi-
fied anemia as mild (11–12.9 for males and 11–11.9 g/dl
for females) moderate (8–11 g/dl) and sever (<8 g/dl).
Biochemical analyses were done on HumaStar 80 clinical
chemistry analyzer (Human Diagnostics, Germany) using
kits supplied by the manufacturer. Serum creatinine con-
centration was assayed by a kinetic Jaffe’ method as mg/dl
with calibration traceable to IDMS reference material
NIST SRM 909B level 2. Kidney function (eGFR) was
assessed according to the simplified version of the Modifi-
cation of Diet in Renal Disease (MDRD) study equation
[12]: 186 × SCr(mg/dl)-1.154 × age(years)-0.203 × 0.742 (if
female) × 1.210 (as our population are Africans).
Staging of renal function was based on the National
Kidney Foundation Disease Outcomes Quality Initiative
(K/DOQI) classification [13]. Stage 1 renal impairment
was defined as normal or increased eGFR (eGFR ≥
90 ml/min/1.73 m2). Mild, moderate, and severe renal
impairment were defined as eGFR 60–89.9, 30–59.9 and
15–29.9 ml/min/1.73 m2, respectively. For the purposes
of this study, impaired renal function was defined as
eGFR <60 ml/min/1.73 m2.
Statistical analysis
The data was entered in to “EpiInfo version 3.1” and was
exported to SPSS version 20.0 statistical software for
analysis Normally distributed and continuous variables
were expressed as mean ± standard deviation (SD), and
non-normally distributed variables were presented as
medians (quartiles 25 and 75%). Chi-square (×2) test
was used to compare proportions. Multivariate logistic
regression was used to calculate adjusted odds ratios
(OR) and the corresponding 95% confidence intervals
(CI). P value < 0.05 was used to indicate statistical
significance.
Ethical consideration
Study protocol was approved by the Institutional Review
Board of College of Medicine and Health Sciences of
Wollo University. Official letter of cooperation was writ-
ten to Dessie referral hospital, and permission from the
ART clinic of the hospital, where the data collection took
place was obtained. Confidentiality of the patient’s
Fiseha et al. BMC Hematology  (2017) 17:1 Page 3 of 6information was strict and no information was handed
over to a third party.
Results
Clinical characteristics of the study participants
A total of 373 HIV positive individuals (140 males and
233 females) were assessed for the presence of anemia and
renal impairment at the time of ART initiation at the ART
clinic of Dessie referral hospital. The mean ± SD age of
the study participants was 34.6 ± 10.8 years, ranging from
18 to 76 years and 89.3% of them were below 50 years old.
The median CD4 count was 182.0 cells/mm3 (IQR:
94–313), and 80.4% had CD4 < 350 cells/mm3. Only,
97 (26%) of study participants had a positive history of
opportunistic infections (OI), and 147 (39.4%) and 135
(36.2%) were classified as WHO stage III/IV. Mean
haemoglobin (Hgb) level was 12.84 ± 2.12 g/dl. Mean
serum creatinine (SCr) level was 0.94 ± 0.43 mg/dl.
The mean eGFR value was 115.91 ± 43.45 ml/min/
1.73 m2 (Table 1).
Prevalence of anemia
Anemia was present in 34.4% of the study participants,
with 20.5, 12.3 and 1.6% described as mild, moderate
and severe anemia respectively. The overall prevalence
of anemia was 41.4% among males and 34.3% among
females, and gender had no a significant influence on
the overall prevalence of anemia at the time of ARTTable 1 Demographic and clinical characteristics of HIV infected
adults at the time of ART initiation in DRH of Southern Wollo,
South Eastern Ethiopia, 2015 (n = 372)
Characteristics
Age (year), mean ± SD 34.57 ± 10.8
Age group, n (%) 18–29 Years 131 (35.1)
30–39 Years 131 (35.1)
40–49 Years 71 (19.0)
>50 Years 40 (10.7)
Sex, n (%) Male 140 (37.5)
Female 233 (62.5)
Opportunistic infections, n (%) Yes 97 (26.0)
No 276 (74.0)
WHO clinical stage, n (%) Stage I/II 226 (60.6)
Stage III/IV 147 (39.4)
CD4 count (Cells/mm3), median (IQR) 182 (94–313)
CD4 count (Cells/mm3), n (%) <200 206 (55.2)
200–350 94 (25.2)
>350 73 (19.6)
Haemoglobin (Hgb), mean ± SD 12.84 ± 2.12
Serum Creatinine (SCr), mean ± SD 0.94 ± 0.43
eGFR, mean ± SD 115.9 ± 43.45initiation in our study participants (P = 0.169). The over-
all prevalence of anemia was 29.1, 36.2, 34.6 and 55.9%
among patients whose age group was within 18–29,
30–39, 40–49 and >50 years, respectively, and was sig-
nificantly higher among participants > 50 years old
than ≤ 50 years old: 70.0% vs. 34.1% (P = 0.004). The
overall prevalence of anemia significantly increased
with WHO stage of HIV disease, ranging from 19.1% in
Stage 1 to 63.6% in Stage 4 (P = 0.007) (Table 2).
Based on baseline CD4 count, there was a significant
difference in the prevalence of anemia within the three
CD4 categories. The prevalence of overall anemia
increased with decreasing CD4 count, with 48.5% among
patients with CD4 count < 200 cells/mm3, and 30.9 and
12.3% among those with CD4 count of 200–350 and
>350 cells/mm3 respectively (P < 0.001). However, there
were no significant differences in anemia prevalence
among participants with and without a history of oppor-
tunistic infection (P = 0.800). Abnormal serum creatinine
(SCr), defined as SCr levels > 1.5 mg/dl, was present in
6.1% of participants and was associated with a higher
prevalence of anemia than its absence: 95.2% vs. 31.3%
(P < 0.001) (Table 2).
Renal insufficiency, defined as an estimated GFR
(eGFR) less than 90 mL/min/1.73 m2, was present in
104 (27.9%) of participants at the time of ART initiation.
Of these, 64 (17.2%), 38 (10.2%) and 2 (0.5%) of themTable 2 Overall prevalence of Anemia among HIV infected
adults at the time of ART initiation in DRH of Southern Wollo,
South Eastern Ethiopia, 2015 (n = 372)
Variables N (%) P-value
Age
≤ 50 years 117 (34.1) < 0.001
> 50 years 21 (70.0)
Sex
Male 58 (41.4) 0.169
Female 80 (34.3)
History of opportunistic infections
Yes 35 (36.1) 0.800
No 103 (37.3)
WHO clinical stage
Stage I/II 66 (31.1) 0.007
Stage III/IV 72 (44.7)
CD4 count
< 200 cells/mm3 100 (48.5) < 0.001
200–350 cell/mm3
> 350 cells/mm3 9 (12.3)
Serum creatinine
> 1.5 mg/dl 36 (94.7) < 0.001
≤ 1.5 mg/dl 102 (30.4)
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eGFR of 60–89.9, 30–59.9 and 15–29.9 mL/min/
1.73 m2, respectively. The prevalence of anemia was 74%
in people with renal insufficiency (Table 3). The preva-
lence of anemia in people without renal insufficiency
was 22.7%. The prevalence of overall anemia among partici-
pants with impaired renal function (eGFR < 60 mL/min/
1.73 m2) was significantly higher (94.3%) than those
without impaired renal function (28.5%, P < 0.001).
The prevalence of anemia among HIV- infected patients
with renal insufficiency was significantly higher compared
to patients with normal renal function (P < 0.001). The
prevalence of anemia increased with stage of renal insuffi-
ciency, ranging from approximately 23.7% in Stage 1 to
100% in Stage 4. The prevalence of overall anemia, and of
mild anemia increase significantly with stage of renal
insufficiency (both P < 0.001), but not the prevalences of
moderate and severe anemia (P = 0.080 and P = 0.115).
Impaired renal function, defined as eGFR < 60 mL/min/
1.73 m2, was associated with an increased risk of overall
anemia with an odds ratio of 3.311 (2.725–4.022, P < 0.001).
Impaired renal function contribute to the risk of all
forms of anemia with odds ratios of 3.964 (2.761–5.691,
P < 0.001), 2.207 (1.162–4.192, P = 0.019) and 5.886
(1.018–12.030, P = 0.026) for mild, moderate and severe
anemia, respectively.
Discussion
Anemia is a frequent complication of HIV infection and
can have serious implications, varying from functional
and quality of life decrements to an association with dis-
ease progression and decreased survival [14]. As recovery
from anemia increase survival, screening for anemia
among HIV positive population at base line should be
aggressive and critical not only to reduce mortality, but
also in suggesting ways to improve quality of life [2, 8].
In this study, we investigated the prevalence of anemia
and its association with impaired renal function among
a population of HIV-infected patients at the time of
ART initation.
Based on the results of this study, more than 37% of
HIV infected patients initiating ART had anemia, with
23.1, 12.3 and 1.6% mild, moderate and severe anemia,
respectively. Our prevalence estimate of anemia was
lower than those reported in studies conducted in otherTable 3 Prevalence of anemia associated with worsening renal insu
Stage (eGFR, ml/min/1.73 m2) Description
1 (>90) Normal or high GFR
2 (60–89.9) Mild renal insufficiency
3 (30–59.9) Moderate renal insuffic
4 (15–29.9) Severe renal insufficienparts of the country; 42.3, 42.9 and 86.5% in North West
Ethiopia, Addis Ababa and South Ethiopia, respectively
[15–17]. This is also lower than estimate of 70.5% preva-
lence of anemia among HIV-infected patients at treat-
ment initiation but higher than 25.8% estimates in
Southern Africa [18, 19]. These differences in anaemia
prevalence might be due to the heterogeneity of study
population and differences in the study settings in terms
of nutritional status and stages of HIV infection. Fur-
thermore, despite the fact that a WHO definition for
anemia was proposed more than 45 years ago [20], com-
parative studies of HIV-related anemia have used non-
standardized definitions, varying prevalence estimates
between settings and biasing the scope of the problem.
Reduced renal function is an important complication of
HIV infection associated with a significant risk of CVD,
heart failure and faster disease progression [21, 22]. In this
study, 104 (27.9%) of HIV infected patients had renal
insufficiency. This finding is nearly similar to that from a
study done in Zambia where renal insufficiency was found
in 33.5% of the HIV infected patients initiating ART [23],
but lower than 36.9% reported in the Uganda study [24]
and 38 and 39% reported in two Nigeria studies [25, 26]
who used the same cut off of eGFR <90 mL/min/1.73 m2
to define renal insufficiency. However, the Uganda
study used Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) and the Zambian and Nigerian
studies used Cockroft and Gault (CG) formula for cal-
culating eGFR. When renal impairment was defined as
eGFR < 60 mL/min/1.73 m2, 10.7% of our HIV infected
participants had impaired renal function. Our finding is
lower than the recent finding of 24% in Nigeria [26]
and higher than findings in Ghanaian HIV infected
HAART-naïve patients that reported 9.1% using the
same definition with MDRD formula [27].
As decreased renal function at baseline may identify
HIV infected patients at increased risk of mortality and
kidney disease progression [28], regular screening of
these population for renal impairment at base line
should be critical not only to reduce mortality but also
to improve patient outcomes. One of the many known
complications of decreased renal function is anemia, a
condition in which the number of circulating red blood
cells, and therefore the level of hemoglobin, is lower
than normal. Anemia is a strong predictor of mortalityfficiency (n = 372)
N (%) Anemia N
(% total)
269 (72.1) 61 (74.0)
64 (17.2) 38 (60.3)
iency 38 (10.2) 36 (94.7)
cy 2 (0.5) 2 (100)
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impairment or HIV infection [3, 5, 10], and HIV-infected
persons with renal impairment had a greater risk of de-
veloping anemia than patients with either risk factor
alone [11]. The additional risk of anemia among HIV-
infected patients with renal impairment when compared
to HIV-infected patients with normal renal function
suggests a higher risk of anemia-associated morbidity
and mortality.
In the present study we found that HIV- infected
patients with renal insufficiency have a higher prevalence
of anemia (74%) compared to patients with normal renal
function (74% vs. 22.7%, P < 0.001). The results of the
above study suggest that HIV infection and impaired
renal function interact to exacerbate hemoglobin
decline, even among persons receiving effective HIV
treatment [11]. The prevalence of anemia increased with
stage of renal impairment, from 23.7% at stage 1 to
100% at stage 4. HIV- infected patients with impaired
renal function had a risk of having mild, moderate and
severe anemia that was 3.9, 2.2 and 5.8 times greater
than those without impaired renal function. Dickson and
co-authors [29] recently reported that anemia increases
in prevalence with severity of renal disease, and anemia
in either renal insufficiency or HIV patients is associated
with increased morbidity and mortality; therefore, a
prompt diagnosis of anemia is warranted, as it may im-
pact clinical treatments and outcomes in this population.
Moreover, as recovery from anemia increase survival,
screening for anemia among HIV positive population
with or without renal impairment at base line should be
aggressive and critical not only to reduce mortality, but
also in suggesting ways to improve quality of life.
Conclusion
In conclusion, the prevalence of anemia and renal insuf-
ficiency was higher in this HIV infected adult population
at the time of ART initiation. HIV infected patients with
renal insufficiency had a higher prevalence of anemia
compared to patients with normal renal function. Thus,
screening of these patients for anemia at base line
should be critical not only to reduce mortality but also
to improve clinical outcomes.
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